Abiopharma

🔍 Vogt Frederick G (Director)

Company: IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Report Date: 2025-09-02

Detailed Transactions and Holdings:

• Acquired 52,086 shares of Common Stock (Direct)
  Date: 2025-09-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 456,690.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 22,127 shares of Common Stock at $2.19 per share (Direct)
  Date: 2025-09-02 | Code: F | equity_swap_involved: 0 | shares_owned_after: 434,563.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 10,417 shares of Restricted Stock Units (Derivative)
  Date: 2025-09-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 20,385.00 | transaction_form_type: 4 | Footnotes: F4, F5, F5, F6
• Sold 41,669 shares of Restricted Stock Units (Derivative)
  Date: 2025-09-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 250,013.00 | transaction_form_type: 4 | Footnotes: F4, F5, F5, F7

Footnotes:

• F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
• F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
• F3: Represents common stock remaining after deducting the common stock withheld for taxes.
• F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• F5: The remaining RSUs will vest in equal quarterly installments.
• F6: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person.
• F7: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person.